<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443677</url>
  </required_header>
  <id_info>
    <org_study_id>HD2000</org_study_id>
    <nct_id>NCT00443677</nct_id>
  </id_info>
  <brief_title>Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)</brief_title>
  <acronym>HD2000</acronym>
  <official_title>Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Studio Linfomi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Studio Linfomi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the toxicities of the COPPEBVCAD vs BEACOPP vs ABVD
      regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the toxicity of the COPPEBVCAD vs BEACOPP vs ABVD regimens</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the results in terms of response, failure free survival and relapse free survival of the three regimens</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Advanced Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>abvd</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>beacopp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>coppebvcad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COPPEBVCAD vs BEACOPP vs ABVD</intervention_name>
    <arm_group_label>abvd</arm_group_label>
    <arm_group_label>beacopp</arm_group_label>
    <arm_group_label>coppebvcad</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of Hodgkin disease

          -  Clinical stage IIB, III, IV

          -  No prior treatment for Hodgkin disease or other malignancy

          -  Age 18-65 year

          -  Good cardiac, pulmunar, renal and hepatic function

          -  Performance status 0-3 (Karnofsky 100- 40)

          -  Written Informed Consent

        Exclusion Criteria:

          -  HIV positivity

          -  Large cell, anaplastic, CD30+ lymphoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Gobbi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GISL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilio Iannitto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GISL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Polimeno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GISL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Oncologico Modenese</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2007</study_first_posted>
  <last_update_submitted>March 19, 2009</last_update_submitted>
  <last_update_submitted_qc>March 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>sponsor</name_title>
    <organization>Gruppo Italiano Studio Linfomi</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

